Print

TMB-108

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Sequential Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered Ibalizumab in HIV-Negative, At-Risk Volunteers

Trial Details:

I Completed
TaiMed Biologics, Aaron Diamond AIDS Research Center, Bill and Melinda Gates Foundation February 01, 2011
Ibalizumab Ibalizumab Antibody
Ibalizumab Passive Immunization
USA 24
NCT01292174
https://clinicaltrials.gov/ct2/show/NCT01292174?term=tmb355&rank=2